The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection.
Bartlett
John G
JG
Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA. jb@jhmi.edu
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000187:drug effects*; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000266:history / Q000382:microbiology*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D014640:Vancomycin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D008795:Metronidazole; D014640:Vancomycin